NCT01995058View on ClinicalTrials.gov

Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Prostate CancerCastration Resistant Prostate CancerProstatic Neoplasms
Interventions
DRUG

cabozantinib

Tablets taken orally

DRUG

abiraterone

Tablets taken orally daily

DRUG

prednisone

Tablets taken orally twice daily

Trial Locations (20)

27607

Raleigh

29414

Charleston

29572

Myrtle Beach

29605

Greenville

30318

Atlanta

30607

Athens

61615

Peoria

67214

Wichita

75246

Dallas

77024

Houston

80012

Aurora

80045

Aurora

84112

Salt Lake City

85258

Scottsdale

85710

Tucson

86336

Sedona

89148

Las Vegas

92108

San Diego

93030

Oxnard

97062

Tualatin

Sponsors

Lead Sponsor

Exelixis
All Listed Sponsors
lead

Exelixis

INDUSTRY